Álvaro García‐Ropero

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Rodolfo San Antonio et al. · Journal of the American College of Cardiology · 2019 · 633 citations

Myocardial Energetics, Cardiomyopathy, Heart Failure +8

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

Carlos G. Santos‐Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibáñez et al. · Journal of the American College of Cardiology · 2020 · 492 citations

Diabetes Management, Heart Failure, Cardiovascular Disease +7

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure

Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Rodolfo San Antonio et al. · JACC. Cardiovascular imaging · 2020 · 183 citations

Metabolic Syndrome, Left Ventricular Fibrosis/stiffness, Heart Failure +9

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

Carlos G. Santos‐Gallego, Álvaro García‐Ropero, Donna Mancini et al. · Cardiovascular Drugs and Therapy · 2019 · 68 citations

Metabolic Syndrome, Empa-tropism Trial, Cardiovascular Translational Research +11